文献速递前列腺癌

基于活检的基底-管腔亚型分类器在高危前列腺癌中的应用:NRG Oncology/RTOG 9202、9413和9902三项3期试验的联合分析

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
PubMed 文献 · Eur Urol Oncol · 2024-11-13

本研究对NRG/RTOG 9202、9413和9902三项随机3期试验的活检样本进行前列腺亚型分类器(PSC)基底/管腔分型,评估其在高危前列腺癌患者接受长期(24-28个月)与短期(4个月)雄激素剥夺治疗(ADT)时的预后和预测价值。结果显示基底亚型预后更差,且长期ADT的获益仅在基底型肿瘤中观察到,PSC可能用于个体化ADT推荐,但需前瞻性研究进一步验证。

要点

  • 基底亚型与更差的转移无生存(MFS)、前列腺癌特异性死亡(PCSM)和总生存(OS)相关。
  • 长期ADT仅改善基底型肿瘤的10年PCSM,管腔型未见获益。
  • PSC是预后和预测生物标志物,可能个体化ADT推荐,但需前瞻性验证。

核心结论

  • PSC既是预后生物标志物也是预测生物标志物,可识别从长期ADT获益的患者。
  • PSC亚型可用于个体化高危前列腺癌患者的ADT推荐,但需前瞻性研究进一步验证。

研究设计与样本

  • 对NRG/RTOG 9202、9413和9902三项随机3期试验的活检样本进行PSC基底/管腔分类。
  • 采用Cox比例风险模型(MFS、OCM、OS)、Fine-Gray模型(BF、DM、PCSM)和限制性平均生存时间(RMST)模型评估预后和预测价值。

主要发现

  • 多变量分析中,基底亚型与更差的MFS相关(HR 1.8 [1.3-2.5],p < 0.001)。
  • 基底亚型与更差的PCSM相关(亚分布HR 2.4 [95% CI 1.4-4.1],p = 0.001)。
  • 基底亚型与更差的OS相关(HR 1.8 [1.3-2.6],p < 0.001)。
  • 10年PCSM管腔亚型较基底亚型改善15%(11% [95% CI 6-15%] vs 26% [95% CI 17-35%])。
  • ADT疗程(长期 vs 短期)与PSC亚型(基底 vs 管腔)对PCSM存在显著交互作用(pinteraction = 0.008),长期ADT仅改善基底型肿瘤的10年PCSM(5% [95% CI 0-11%] vs 42% [29-56%],p < 0.001)。

临床怎么用

  • PSC亚型可能用于个体化高危前列腺癌患者的ADT推荐,但需前瞻性研究进一步验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Long-term (LT) androgen deprivation therapy (ADT) has been found to be beneficial to patients with high-risk prostate cancer (PCa). However, administration of LT-ADT to all patients with high-risk PCa may lead to overtreatment. Enhanced risk stratification using genomic classifiers (such as the recently developed prostate subtyping classifier [PSC]) might be useful. This study aims to characterize the prognostic and predictive ability of the PSC in patients with high-risk PCa undergoing radiotherapy long-term (LT; 24-28 mo) versus short-term (ST; 4 mo) ADT. METHODS: Biopsy samples from three randomized, phase 3 trials-NRG/RTOG 9202, 9413, and 9902-were classified as either PSC basal or luminal. The prognostic and predictive values of PSC for each oncologic endpoint (biochemical failure [BF], distant metastasis [DM], metastasis-free survival [MFS], PCa-specific mortality [PCSM], overall survival [OS]) and other cause-mortality (OCM) were assessed with Cox proportional hazards (MFS, OCM, and OS), Fine-Gray (BF, DM, and PCSM), and restricted mean survival time (RMST) models. KEY FINDINGS AND LIMITATIONS: On a multivariable analysis, the basal subtype was found to have a worse prognosis for MFS (hazard ratio [HR] 1.8 [1.3-2.5], p < 0.001), PCSM (subdistribution HR 2.4 [95% confidence interval {CI} 1.4-4.1], p = 0.001), and OS (HR 1.8 [1.3-2.6], p < 0.001). Ten-year PCSM was 15% better for the luminal subtype than for the basal subtype (11% [95% CI 6-15%] vs 26% [95% CI 17-35%]). A significant interaction between ADT duration (LT vs ST) and PSC subtype (basal vs luminal) was observed for PCSM (pinteraction = 0.008), leading to the observation that 10-yr PCSM was improved with LT-ADT only in patients with basal-type tumors (5% [95% CI 0-11%] vs 42% [29-56%], p < 0.001). Improvements in 10-yr RMST with LT-ADT were greater for basal tumors for oncologic endpoints with the exception of OCM. CONCLUSIONS AND CLINICAL IMPLICATIONS: PSC is both a prognostic and a predictive biomarker for patients who benefit from LT-ADT. PSC subtypes may be used to personalize ADT recommendations for patients with high-risk PCa, pending further validation in a prospective study. PATIENT SUMMARY: In this study, we tried to understand the usefulness of a new genomic test in patients with high-risk, nonmetastatic prostate cancer who underwent radiation therapy and hormonal therapy (HT). We found that this test can help determine a patient's prognosis (eg, a patient's chance of having the cancer return) and, more importantly, personalize treatment decisions by understanding which patients may benefit from long-term HT. This has the potential to save many patients who may not benefit from prolonged HT from "overtreatment" or the unnecessary side effects of such treatment.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Patel KR, Nguyen PL, Proudfoot JA, et al. Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. Eur Urol Oncol. 2024. PMID: 39542826. doi:10.1016/j.euo.2024.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。